Biotech Stock Performance Review -- Agenus, Akebia Therapeutics, Acorda Therapeutics, and Advaxis
NEW YORK, October 20, 2017 /PRNewswire/ --
If you want a Stock Review on AGEN, AKBA, ACOR, or ADXS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today, DailyStockTracker.com features the Biotech industry, which comprises companies that use live organisms or their products, such as bacteria or enzymes, to manufacture their drugs. Equities under evaluation this morning are: Agenus Inc. (NASDAQ: AGEN), Akebia Therapeutics Inc. (NASDAQ: AKBA), Acorda Therapeutics Inc. (NASDAQ: ACOR), and Advaxis Inc. (NASDAQ: ADXS). These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
http://dailystocktracker.com/register/
Agenus
On Thursday, shares in Lexington, Massachusetts headquartered Agenus Inc. recorded a trading volume of 4.71 million shares, which was above their three months average volume of 1.06 million shares. The stock ended the session 5.10% lower at $4.47. The Company's shares have gained 6.68% in the last one month and 8.50% on an YTD basis. The stock is trading 9.05% above its 50-day moving average and 12.75% above its 200-day moving average. Moreover, shares of Agenus, which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 52.15.
On October 13th, 2017, Agenus announced that Health Canada granted marketing authorization to GlaxoSmithKline's shingles vaccine, Shingrix, that contains Agenus' proprietary immune adjuvant QS-21 Stimulon® adjuvant. The approval in Canada marks the first approval for Shingrix and the first approval of a vaccine containing QS-21 Stimulon. Your complete research report on AGEN can be retrieved for free at:
http://dailystocktracker.com/registration/?symbol=AGEN
Akebia Therapeutics
Cambridge, Massachusetts headquartered Akebia Therapeutics Inc.'s stock closed the day 1.22% lower at $17.78. A total volume of 452,600 shares was traded, which was above their three months average volume of 376,020 shares. The Company's shares have advanced 0.45% in the past month, 28.65% in the previous three months, and 70.80% since the start of this year. The stock is trading 3.75% and 36.39% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Akebia Therapeutics, which focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology, have an RSI of 45.84.
On October 04th, 2017, Akebia Therapeutics announced that it granted seven newly hired employees options to purchase an aggregate of 33,000 shares of its common stock, with a per share exercise price of $19.67, the closing price on the grant date. These options will vest as to 25% of the total number of shares subject to the option on the first anniversary of the grant date. The remaining 75% of shares will vest ratably on the first day of each calendar quarter over the next three years. A free report on AKBA is just a click away at:
http://dailystocktracker.com/registration/?symbol=AKBA
Acorda Therapeutics
Shares in Ardsley, New York headquartered Acorda Therapeutics Inc. recorded a trading volume of 464,373 shares. The stock ended yesterday's trading session 1.29% lower at $26.70. The Company's shares have advanced 11.72% in the past month, 29.30% in the previous three months, and 42.02% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 14.01% and 26.29%, respectively. Furthermore, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have an RSI of 61.38.
On October 06th, 2017, research firm Goldman resumed its 'Sell' rating on the Company's stock, with a target price of $20 per share.
On October 10th, 2017, Acorda Therapeutics announced that it will host a conference call and webcast on October 31st, 2017, at 8:30 a.m. ET to report its Q3 2017 financial results and pipeline updates. The presentation will be available under the Investors section of the Company's website. Sign up for your complimentary research report on ACOR at:
http://dailystocktracker.com/registration/?symbol=ACOR
Advaxis
Princeton, New Jersey-based Advaxis Inc.'s stock finished Thursday's session 2.24% lower at $3.93 with a total trading volume of 696,959 shares. The Company's shares are trading below their 50-day moving average by 27.04%. Shares of the Company, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have an RSI of 34.46. Register for free on DailyStockTracker.com and download the latest research report on ADXS at:
http://dailystocktracker.com/registration/?symbol=ADXS
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207) 331.3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
